Merck - Vaccine Impact

Permalink Gallery
Former CDC Director Julie Gerberding sells 38,368 shares of Merck Stock for $2.3 Million

Headline, News

Former CDC Director Julie Gerberding sells 38,368 shares of Merck Stock for $2.3 Million

Julie Gerberding was in charge of the Centers for Disease Control and Prevention (CDC) from 2002 to 2009, which includes the years the FDA approved the Merck Gardasil vaccine. Soon after she took over the CDC, she reportedly completely overhauled the agency’s organizational structure, and many of the CDC’s senior scientists and leaders either left or announced plans to leave. Some have claimed that almost all of the replacements Julie Gerberding appointed had ties to the vaccine industry. Gerberding resigned from the CDC on January 20, 2009, and took over as the president of Merck’s Vaccine division, a 5 billion dollar a year operation, and the supplier of the largest number of vaccines the CDC recommends. It was reported earlier this month that Dr. Gerberding, now the executive vice president of pharmaceutical giant Merck, sold 38,368 of her shares in Merck stock for $2,340,064.32. She still holds 31,985 shares of the company’s stock, valued at about $2 million.

Permalink Gallery
Parent Denied Opportunity to Sue Merck After Collecting $250K “Blood Money” for MMR Vaccine Death of Child

Headline, News

Parent Denied Opportunity to Sue Merck After Collecting $250K “Blood Money” for MMR Vaccine Death of Child

Erin Holmes got $250,000 she didn’t want, “blood money” her husband didn’t want to spend. The money came from the Vaccine Injury Compensation Program for her son, Jacob, who died in 2002 from a brain condition after receiving his measles-mumps-rubella and varicella vaccines. The Vaccine Injury Compensation Program is funded by taxpayers via a tax on vaccines. Holmes didn’t want the money – but as an “angry parent” she wanted to do something more. So she reached out to a lawyer in Las Vegas who told her that the money she collected from the compensation program was “Jacob’s money” – and she could still sue for her own suffering. She filed a wrongful death lawsuit against Merck and Co. – a manufacturer of MMR, varicella and other vaccines – alleging “negligence, strict product liability, negligent design, failure to warn, misrepresentation, express warranty, implied warranty of merchantability, implied warranty of fitness for a particular purpose, and punitive damages,” according to court documents. But the 9th U.S. Circuit Court of Appeals ruled that Holmes could not sue for negligent design or failure to warn, because the National Childhood Vaccine Injury Act pre-empted Holmes’ strict product liability, negligent design and failure to warn claims. “If we were to conclude that the parents of those suffering a vaccine-related injury could bring design defect and failure to warn claims … we would be acting contrary to the statute’s central purpose of managing vaccine manufacturers’ liability because our construction would do little to protect the vaccine manufacturers from suit,” the court said in its opinion.

Permalink Gallery
Merck’s Sales Soar on Measles Vaccine After Disney Outbreak

Headline, News

Merck’s Sales Soar on Measles Vaccine After Disney Outbreak

Bloomberg announced this week that Merck's MMR vaccine sales more than quadrupled after the California Disney measles outbreak. Of course, there is no single measles vaccine currently on the market, and one has to purchase the MMR (measles, mumps, rubella) vaccine which is a 3 in 1 combo vaccine. Merck has been involved in a long federal lawsuit with allegations of fraud over the mumps portion of the MMR vaccine, in a case filed back in 2010 by two whistleblowers, virologists who worked for Merck. There is also evidence that the MMR vaccine is killing more people than the measles virus, as there have been no deaths associated with measles according to the CDC, while there have been 108 deaths reported after the measles vaccine in the Vaccine Adverse Event Reporting System (VAERS). In addition, reports show that between 50% and 86% of those who came down with measles in the Disney outbreak were actually already vaccinated. None of that matters to Merck, obviously, as sales of the measles vaccine grew by over 24% during the first quarter of 2015.

Permalink Gallery
Gardasil Vaccine Promoted To 12-Year Old Boys To Double The Market

News

Gardasil Vaccine Promoted To 12-Year Old Boys To Double The Market

What's the best way to attract new patients for a vaccine heavily marketed to only girls? Why open up the market to boys of course. The HPV vaccine is possibly the biggest vaccine hoax in the last century being nothing more than a worldwide exercise in profiteering at the expense of children's health. Another massively flawed study (basically routine for the HPV vaccine) will give Gardasil manufacturer, Merck & Co. the green light to once again create a vaccine awareness campaign on the pretext that it prevents mouth and throat cancers. There are truthfully no safe vaccines, however the HPV vaccine is one of the 5 vaccines I strongly recommend to avoid. It is perhaps the one vaccine based on the most misrepresented data and unproven assumptions.

Permalink Gallery
Supreme Court in India to Rule on Merck Fraud Regarding HPV Vaccine Deaths

News, Uncategorized

Supreme Court in India to Rule on Merck Fraud Regarding HPV Vaccine Deaths

Around the world legal problems regarding the HPV vaccine continue to multiply for Merck, yet this news is mostly censored out of the mainstream media. With multiple lawsuits pending in France over injuries due to the Gardasil HPV vaccine, one former Merck doctor in France even came out and stated that Gardasil will become "the greatest medical scandal of all time." In contrast, here in the U.S. any mainstream journalist that dares to suggest there are problems with the Gardasil vaccine puts their career on the line. Just ask Katie Couric, who dared to interview the mother of a young woman who died from the Gardasil vaccine. She was forced to issue an apology and have the assistant Surgeon General appear on her show to assure everyone the vaccine was safe. What is not revealed in the mainstream media, however, is that the U.S. government holds patents on Gardasil and also earns royalties from the sale of the vaccine. In the meantime, countries around the world are taking action to stop the carnage resulting from the HPV vaccine. Perhaps the most high-profile case you will never read about in the U.S. mainstream media is an upcoming Supreme Court hearing in India with a ruling due next month (August 2014). Merck has been charged with fraud and causing the death of young girls in India with vaccine trials due to the development of the HPV vaccine, sponsored by the U.S. organization PATH, with funding from the Bill and Melinda Gates Foundation. Last year (2013), we published a report from Christina England on a 43-page document produced by the Indian Parliament accusing the U.S. group, PATH, of committing illegal and improper activities in support of commercial interests in the development of the HPV vaccine in India, which led to the deaths of several young Indian girls. A few weeks later, Anita Jain, the India Editor of the British Medical Journal, published her own comments on the ethical violations conducted in India in the development of Gardasil, and questioned the wisdom of rolling out the Gardasil vaccine to the entire country, citing safety and efficacy concerns. Now, the India Supreme Court will decide on the case. But will the U.S. mainstream media even cover this story? So far, they have not.

Permalink Gallery
Sanofi Sued in France over Gardasil Vaccine – Could this be the Beginning of the End for Gardasil?

News

Sanofi Sued in France over Gardasil Vaccine – Could this be the Beginning of the End for Gardasil?

Mainstream news media widely reported last month that a French teenager had filed a lawsuit against French pharmaceutical company, Sanofi Pasteur, and France's health regulators, over side-effects that were caused by the Gardasil HPV vaccine. Jean-Christophe Coubris Bordeaux is suffering from multiple sclerosis as a result of the Gardasil HPV vaccine. This story is quite significant for two major reasons. First, you will never read a story like this happening in the United States, because you cannot sue a pharmaceutical company for damages as a result of vaccines in the United States. U.S. law, upheld by the U.S. Supreme Court in 2011, gives total immunity to pharmaceutical companies in the U.S. for any damages related to vaccine products. Secondly, negative news regarding lawsuits or government action against vaccines in countries outside the U.S. are almost never reported in the U.S. media. How this one slipped through the cracks is not clear to me at this point. It could be that they believe they have an air-tight defense in this lawsuit, and that the overall media exposure for them will be positive on this. Or, it could be that Sanofi, a French company, does not have the same media lobbyists and influence that American and UK drug firms seem to have. The news regarding Gardasil outside the U.S. is very negative, while the U.S. media has continued to propagate the notion that Gardasil is one of the safest vaccines on the market. Japan recently announced it had stopped recommending Gardasil vaccines and has begun a full investigation into the safety of the vaccine, amid numerous reports of severe injuries from side effects. In addition to all the bad publicity Gardasil is receiving over severe side effects, including death, a study that was completely ignored by the U.S. media earlier this year, linked the HPV vaccine to premature menopause in teenage girls. In another recent report that was completely ignored by the mainstream U.S. media, it was found that the Bill Gates funded group, PATH, which participated in HPV vaccine drug trials in India, violated the law resulting in fatalities of young girls during the drug trials. An investigation is ongoing in India. Could we be looking at another Merck disaster similar to Vioxx, which reportedly killed more than 60,000 people before it was removed from the market?